PIK RELATED KINASES IN THE RESPONSE TO DNA DAMAGE BY UV
PIK RELATED KINASES IN THE RESPONSE TO DNA DAMAGE BY UV
批准号:
6268424
负责人:
PAUL NGHIEM
金额:
$6.6万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-04-01 至 1999-03-31
关键词:
中文摘要
太阳紫外线(UV)辐射对DNA的损伤是皮肤的主要原因
癌症,美国最常见的癌症类型。一种细胞“紫外线”
涉及P53肿瘤抑制蛋白激活的反应
进化来保护基因组免受这种太阳威胁。一个完好无损的
复制,防止突变的永久并入。
大约90%的鳞状细胞癌缺乏这种紫外线反应,表明
致癌。
尽管这种保护途径很重要,但目前还不清楚它是如何
紫外线对DNA的损伤导致P53的诱导。一种叫做ATR的基因已经被
在Schreiber组中克隆,似乎是
基于初步数据的UV-P53反应。ATR属于一种新的
所描述的称为PIK相关蛋白的蛋白家族(磷脂酰基
肌醇激酶相关酶),其中包括突变在
隐性致死性疾病,共济失调毛细血管扩张症。PIK相关的蛋白水解酶
调节细胞应激后的细胞周期停滞,如DNA损伤。
分子和生化方法将被用来检验这一假说
紫外光反应需要ATR或另一个与PIK相关的激酶。
内源性ATR功能将受到抑制,显性负ATR
在可诱导或逆转录病毒系统中表达的等位基因。ATR的作用
然后在UV-DNA反应的个别方面进行检查
损坏。以后的研究将集中在该途径中的其他蛋白质上。
该项目旨在深入了解紫外线的分子机制。
致癌,并可提出预防和预防癌症的方法
治疗皮肤癌和更一般的癌症。
英文摘要
DNA damage by solar ultraviolet (UV) radiation is the major cause of skin
cancer, the most common type of cancer in the US. A cellular "UV
response" involving activation of the p53 tumor suppressor protein has
evolved to protect the genome against this solar threat. An intact
response leads to cell cycle arrest and allows DNA to be repaired prior
to replication, preventing the permanent incorporation of mutations.
Roughly 90% of squamous cell carcinomas lack this UV response indicating
the essential function of this pathway in protecting the genome from UV
carcinogenesis.
Despite the importance of this protective pathway, it is not known how
DNA damage by UV leads to p53 induction. A gene called ATR has been
cloned in the Schreiber group and appears likely to be the mediator of
the UV-p53 response based on preliminary data. ATR belongs to a newly
described family of proteins called the PIK-related kinases (phosphatidyl
inositol kinase-related kinases), which includes the gene mutated in the
recessive lethal disease, ataxia telangiectasia. The PIK-related kinases
mediate cell cycle arrest after cellular stresses such as DNA damage.
Molecular and biochemical approaches will be used to test the hypothesis
that ATR or another PIK-related kinase is required for the UV response.
Endogenous ATR function will be inhibited with a dominant negative ATR
allele expressed in an inducible or retroviral system. The role of ATR
will then be examined in individual aspects of the response to UV-DNA
damage. Later studies will focus on other proteins in this pathway
including putative substrates for the UV-responsive protein.
This project aims to provide insight into the molecular mechanism of UV
carcinogenesis and may suggest approaches for the prevention and
treatment of skin cancer and cancer more generally.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Immunobiology and Immune Therapy for Merkel Cell Carcinoma
-
批准号:9906874
-
项目类别:
-
资助金额:$299.62万
-
财政年份:2019
-
负责人:PAUL NGHIEM
-
依托单位:
Administrative Core
-
批准号:10380820
-
项目类别:
-
资助金额:$18.77万
-
财政年份:2019
-
负责人:PAUL NGHIEM
-
依托单位:
Project 2: Characterizing and overcoming failure to respond to PD-1 blockade therapy
-
批准号:10380818
-
项目类别:
-
资助金额:$40.78万
-
财政年份:2019
-
负责人:PAUL NGHIEM
-
依托单位:
Core 1: Specimen and Data Core
-
批准号:10629194
-
项目类别:
-
资助金额:$33.34万
-
财政年份:2019
-
负责人:PAUL NGHIEM
-
依托单位:
Core 1: Specimen and Data Core
-
批准号:10380821
-
项目类别:
-
资助金额:$35.06万
-
财政年份:2019
-
负责人:PAUL NGHIEM
-
依托单位:
Administrative Core
-
批准号:10629193
-
项目类别:
-
资助金额:$24.79万
-
财政年份:2019
-
负责人:PAUL NGHIEM
-
依托单位:
Project 2: Characterizing and overcoming failure to respond to PD-1 blockade therapy
-
批准号:10629191
-
项目类别:
-
资助金额:$36.8万
-
财政年份:2019
-
负责人:PAUL NGHIEM
-
依托单位:
Immunobiology and Immune Therapyfor Merkel Cell Carcinoma
-
批准号:10629189
-
项目类别:
-
资助金额:$255.68万
-
财政年份:2019
-
负责人:PAUL NGHIEM
-
依托单位:
Immunobiology and Immune Therapyfor Merkel Cell Carcinoma
-
批准号:10380816
-
项目类别:
-
资助金额:$291.28万
-
财政年份:2019
-
负责人:PAUL NGHIEM
-
依托单位:
Mechanisms of UV-induced DNA damage responses and carcinogenesis in skin
-
批准号:9038985
-
项目类别:
-
资助金额:$38.28万
-
财政年份:2015
-
负责人:PAUL NGHIEM
-
依托单位:
Pathogenetic and prognostic studies for improved therapy of Merkel cell carcinoma
-
批准号:8699412
-
项目类别:
-
资助金额:$17.6万
-
财政年份:2014
-
负责人:PAUL NGHIEM
-
依托单位:
Pathogenetic and prognostic studies for improved therapy of Merkel cell carcinoma
-
批准号:9127151
-
项目类别:
-
资助金额:$17.6万
-
财政年份:2014
-
负责人:PAUL NGHIEM
-
依托单位:
Viral oncoprotein targeted immune therapy for Merkel cell carcinoma
-
批准号:8515710
-
项目类别:
-
资助金额:$66.07万
-
财政年份:2013
-
负责人:PAUL NGHIEM
-
依托单位:
Viral oncoprotein targeted immune therapy for Merkel cell carcinoma
-
批准号:8642166
-
项目类别:
-
资助金额:$62.19万
-
财政年份:2013
-
负责人:PAUL NGHIEM
-
依托单位:
Humoral and cellular immunity in polyomavirus-linked Merkel cell carcinoma
-
批准号:8333953
-
项目类别:
-
资助金额:$32.97万
-
财政年份:2011
-
负责人:PAUL NGHIEM
-
依托单位:
Humoral and cellular immunity in polyomavirus-linked Merkel cell carcinoma
-
批准号:8513804
-
项目类别:
-
资助金额:$30.99万
-
财政年份:2011
-
负责人:PAUL NGHIEM
-
依托单位:
Humoral and cellular immunity in polyomavirus-linked Merkel cell carcinoma
-
批准号:8699706
-
项目类别:
-
资助金额:$31.98万
-
财政年份:2011
-
负责人:PAUL NGHIEM
-
依托单位:
Humoral and cellular immunity in polyomavirus-linked Merkel cell carcinoma
-
批准号:8198312
-
项目类别:
-
资助金额:$34.62万
-
财政年份:2011
-
负责人:PAUL NGHIEM
-
依托单位:
Pathogenetic and prognostic studies for improved therapy of Merkel cell carcinoma
-
批准号:8534545
-
项目类别:
-
资助金额:$18.5万
-
财政年份:2009
-
负责人:PAUL NGHIEM
-
依托单位:
Training for Investigative Dermatology
-
批准号:8494572
-
项目类别:
-
资助金额:$14.88万
-
财政年份:2009
-
负责人:PAUL NGHIEM
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: